Population analyses of atorvastatin clearance in patients living in the community and in nursing homes.
The effects of demographic and clinical covariates on the apparent clearance (CL/F) of orally administered atorvastatin, with chronic dosing in a patient population that included the elderly, were studied in 143 patients (atorvastatin: 34 +/- 26 mg/day, mean +/- SD; men (n = 64), age 64.6 +/- 12.1 years, and women (n = 79), age 69.3 +/- 13 years). The time of dose administration had a strong influence on Ka (faster with morning dosing); the factors found to slow CL/F were coadministration of CYP3A inhibitors and advancing age--the latter factor was relevant only in the men, not in the women.
Schwartz
J B
JB
Division of Clinical Pharmacology, University of California, San Francisco, San Francisco, California, USA. Janice.schwartz@ucsf.edu
Verotta
D
D
D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D003430:Cross-Sectional Studies; D065692:Cytochrome P-450 CYP3A Inhibitors; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006538:Heptanoic Acids / Q000493:pharmacokinetics*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D009735:Nursing Homes; D011758:Pyrroles / Q000493:pharmacokinetics*; D012111:Residence Characteristics; D012737:Sex Factors
D008078:Cholesterol, LDL; D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin